STAAR Surgical upgraded to Outperform from Market Perform at William Blair. William Blair analyst Brian Weinstein upgraded STAAR Surgical to Outperform saying he’s grown more comfortable with the company’s ability to forecast demand trends and drive a baseline case for mid- to high-teens revenue growth through 2020. STAAR has a number of potential positive catalysts over the next 12-18 months, including possible opening of the U.S. market again, which could boost growth above these levels and provide upside from current stock levels, Weinstein tells investors in a research note
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.